Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Refaei Belal Ibrahim"'
Autor:
Jamal Zekri, Mohammed Abbas Baghdadi, Refaei Belal Ibrahim, Abdelrazak Meliti, Turki M Sobahy
Publikováno v:
ecancermedicalscience. 16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faf2830866246f5cdd48c2f7bbe069b6
https://doi.org/10.3332/ecancer.2022.1490
https://doi.org/10.3332/ecancer.2022.1490
Autor:
Hossam Abdel Rahman, Refaei Belal Ibrahim, Haleem J. Rasool, Mohamed Youssef Deibas, Ahmed Allithy, Reyad Dada, Jamal Zekri, Kamel Farag, Imran Ahmad, Mohamed Kamal Kamel, Ehab Mosaad Abdelghany, Azhar Nawaz
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(8)
Background Febrile neutropenia (FN) is a life-threatening complication of Docetaxel-based chemotherapy regimens (DBRs). Prophylactic granulocyte-colony stimulating factor (G-CSF) can reduce the risk of FN. This study investigated the effect of G-CSF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b4403a26a596e7ba7dc8f3651471f98
https://pubmed.ncbi.nlm.nih.gov/34342555
https://pubmed.ncbi.nlm.nih.gov/34342555
Autor:
Imran Ahmad, Haleem J. Rasool, Reyad Dada, Ahmed Allithy, Jamal Zekri, Mohamed Youssef Deibas, Kamel Farag, Hossam Abdel Rahman, Ehab Mosaad Abdelghany, Refaei Belal Ibrahim, Mohamed K. Kamel, Azhar Nawaz
Publikováno v:
Journal of Clinical Oncology. 36:e12516-e12516
e12516Background: Primary prophylactic Granulocyte Colony Stimulating Factor (PP-GCSF) is recommended for patients receiving single agent docetaxel (SAD) and docetaxel combination regimens (DCR) to...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56e0f7c614bb55a4d018bac1ac627b32
https://doi.org/10.1200/jco.2018.36.15_suppl.e12516
https://doi.org/10.1200/jco.2018.36.15_suppl.e12516